A review of cardiogenic shock in acute myocardial infarction

Current Cardiology Reviews

Volumn 4, Issue 1, 2008, Pages 34-40

  Khalid, L ^a   Dhakam, Sajid H ^a  

^a AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

Author keywords

Cardiogenic shock; Coronary artery bypass grafting; Fibrinolytic therapy; Intra aortic balloon counterpulsation; Myocardial infarction; Percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; EPTIFIBATIDE; FIBRINOLYTIC AGENT; GLYCERYL TRINITRATE; HEPARIN; HYPERTENSIVE AGENT; MORPHINE; NITRATE; NITRIC OXIDE; NORADRENALIN; OXYGEN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR; STREPTOKINASE;

ACUTE HEART INFARCTION; ANAMNESIS; AORTA BALLOON; ARTIFICIAL VENTILATION; CARDIOGENIC SHOCK; CARDIOPULMONARY BYPASS; CAUSE OF DEATH; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; COUNTERPULSATION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ELECTROCARDIOGRAM; FIBRINOLYTIC THERAPY; FLUID THERAPY; HEART ARRHYTHMIA; HEART ASSIST DEVICE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE REPERFUSION; HOSPITAL PATIENT; HUMAN; HYPOTENSION; INCIDENCE; MONOTHERAPY; MORTALITY; OXYGEN THERAPY; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PHYSICAL EXAMINATION; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; RESUSCITATION; REVIEW; SIDE EFFECT; ST SEGMENT ELEVATION; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; THORAX RADIOGRAPHY; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; VASODILATATION;

EID: 48349110318     PISSN: 1573403X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340308783565456     Document Type: Review

References (92)

1. Killip T 3rd, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two-year experience with 250 patients. Am J Cardiol 1967; 20: 457-64.
2. Goldberg RJ, Gore JM, Alpert JS, et al. Cardiogenic shock after acute myocardial infarction. Incidence and mortality from a community-wide perspective, 1975 to 1988. N Engl J Med 1991; 325: 1117-22.
3. Bates ER, Moscucci M. Post-myocardial infarction cardiogenic shock. In: Brown DL, Ed. Cardiac Intensive Care. Philadelphia, Pa: Saunders, 1998; 215-27.
4. Hochman JS, Boland J, Sleeper LA, et al. Current spectrum of cardiogenic shock and effect of early revascularisation on mortality. Results of an international registry. SHOCK registry investigators. Circulation 1995; 91: 873-81.
5. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med 1999; 341: 625-34.
6. Goldberg RJ, Samad NA, Yarzebski J, Gurwitz J, Bigelow C, Gore JM. Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med 1999; 340: 1162-8.
7. Holmes DR Jr, Bates ER, Kleiman NS, et al. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global utilization of strepto-kinase and tissue plasminogen activator for occluded coronary arteries. J Am Coll Cardiol 1995; 26: 668-74.
8. Becker RC, Gore JM, Lambrew C, et al. A composite view of cardiac rupture in the united states national registry of myocardial infarction. J Am Coll Cardiol 1996; 27: 1321-6.
9. Menon V, Hochman JS. Management of cardiogenic shock complicating acute myocardial infarction. Heart 2002; 88: 531-7.
10. Braunwald EB. Hemodynamic disturbances in acute myocardial infarction. In: Brainwald EB, editor. Heart disease. Philadelphia: W. B. Saunders, 1997; 1233-45.
11. Forrester JS, Diamond G, Chatterjee K, Swan HJ. Medical therapy of acute myocardial infarction by application of hemodynamic subsets (second of two parts). N Engl J Med 1976; 295: 1404-13.
12. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Strepto-chinasi nell'Infarto Miocardico (GISSI). Lancet 1986; 1: 397-402.
13. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomized between alte-plase and streptokinase with or without heparin. The International Study Group. Lancet 1990; 336: 71-5.
14. ISIS-3: a randomized comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. Lancet 1992; 339: 753-70.
15. Rogers WJ, Canto JG, Lambrew CT, et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999. The national registry of myocardial infarction 1, 2 and 3. J Am Coll Cardiol 2000; 36: 2056-63.
16. Hochman JS, Buller CE, Dzavik V. Cardiogenic shock complicating AMI etiologies, management and outcome-overall findings of the SHOCK trial registry. Circulation 1998; 98(Suppl 1): 1-778.
17. Webb JG, Sleeper LA, Buller CE, et al. Implications of the timing of onset of cardiogenic shock after acute myocardial infarction: a report from the SHOCK trial registry. J Am Coll Cardiol 2000; 36: 1084-90.
18. Tipoo FA, Quraishi AR, Najaf SM, et al. Outcome of cardiogenic shock complicating acute myocardial infarction. J Coll Physicians Surg Pak 2004; 14: 6-9.
19. Carnendran L, Abboud R, Sleeper LA, et al. Trends in cardiogenic shock: report from the SHOCK study. Should we emergently revascularize Occluded Coronaries for cardiogenic shock? Eur Heart J 2001; 22: 472-8.
20. Jacobs AK, French JK, Col J, et al. Cardiogenic shock with non-ST-segment elevation myocardial infarction: a report from the SHOCK trial registry. J Am Coll Cardiol 2000; 3 6: 1091-96.
21. Holmes DR Jr, Berger PB, Hochman JS, et al. Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation. Circulation 1999; 100: 2067-73.
22. Lindholm MG, Boesgaard S, Torp-Pedersen C, Kober L, TRACE registry study group. Diabetes mellitus and cardiogenic shock in acute myocardial infarction. Eur J Heart Fail 2005; 7: 834-9.
23. Hochman JS, Buller CE, Sleeper LA, et al. Cardiogenic shock complicating acute myocardial infarction: etiologies, management and outcome: a report from the SHOCK trial registry. J Am Coll Cardiol 2000; 36: 1063-70.
24. Hochman J. Cardiogenic shock. Annual Scientific Sessions, American Heart Association. Dallas, TX; 1998.
25. Bengtson JR, Kaplan AJ, Pieper KS, et al. Prognosis in cardiogenic shock after acute myocardial infarction in the interventional era. J Am Coll Cardiol 1992; 20: 1482-9.
26. Sanborn TA, Sleeper LA, Webb JG, et al. Correlates of one-year survival in patients with cardiogenic shock complicating acute myocardial infarction: angiographic findings from the SHOCK trial. J Am Coll Cardiol 2003; 42: 1373-9.
27. Hands ME, Rutherford JD, Muller JE, et al. The in-hospital development of cardiogenic shock after myocardial infarction: incidence, predictors of occurrence, outcome and prognostic factors. The MILIS Study Group. J Am Coll Cardiol 1989; 14:40-6.
28. Leor J, Goldbourt U, Reicher-Reiss H, Kaplinsky E, Behar S. Cardiogenic shock complicating acute myocardial infarction in patients without heart failure on admission: incidence, risk factors, and outcome. SPRINT Study Group. Am J Med 1993; 94: 265-73.
29. Scheidt S, Ascheim R, Killip, T 3rd. Shock after acute myocardial infarction. A clinical and hemodynamic profile. Am J Cardiol 1970; 26: 556-64.
30. Hasdai D, Califf RM, Thompson TD, et al. Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol 2000; 35: 136-43.
31. Fincke I, Hochman JS, Lowe AM, et al. SHOCK investigators. Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry. J Am Coll Cardiol 2004; 44: 340-8.
32. Hollenberg SM, Kavirisky CJ, Parrillo JE. Cardiogenic Shock. Ann of Intern Med 1999; 131: 47-59.
33. Menon V, White H, LeJemtel T, Webb JG, Sleeper LA, Hochman JS. The clinical profile of patients with suspected cardiogenic shock due to predominant left ventricular failure: a report from the SHOCK trial registry. J Am Coll Cardiol 2000; 36: 1071-6.
34. Hasdai D, Holmes DR Jr, Califf RM, et al. Cardiogenic shock complicating acute myocardial infarction: predictors of death. Global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO) Investigators. Am Heart J 1999; 138:21-31.
35. Duvernoy CS, Bates ER. Management of cardiogenic shock attributable to acute myocardial infarction in the reperfusion era. J Intensive Care Med 2005; 20; 188-98.
36. Nishimura RA, Tajik AJ, Shub C, Miller FA Jr, Ilstrup DM, Harrison CE. Role of two-dimensional echocardiography in the prediction of in-hospital complications after acute myocardial infarction. J Am Coll Cardiol 1984; 4: 1080-7.
37. Picard MH, Davidoff R, Sleeper L, et al. Echocardiographic predictors of survival and response to early revascularization in cardiogenic shock. Circulation 2003; 107: 279-84.
38. Holmes DR Jr, Califf RM, Van de Werf F, et al. Difference in countries use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial. Lancet 1997; 349: 75-8.
39. Connors AF Jr, Speroff T, Dawson NV, et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT investigators. JAMA 1996; 276: 889-97.
40. Richard C, Ricome JL, Rimailho A, Bottineau G, Auzepy P. Combined hemodynamic effects of dopamine and dobutamine in cardiogenic shock. Circulation 1983; 67: 620-6.
41. Gunnar RM, Bourdillon PD, Dixon DW, et al. ACC/AHA guidelines for the early management of patients with acute myocardial infarction. A report of the American college of cardiology/American Heart Association Task Force on Assessment of diagnostic and therapeutic cardiovascular procedures (subcommittee to develop guidelines for the early management of patients with acute myocardial infarction). Circulation 1990; 82: 664-707.
42. Kern MJ, Aguirre F, Bach R, Donohue T, Siegel R, Segal J. Augmentation of coronary blood flow by intra-aortic balloon pumping in patients after coronary angioplasty. Circulation 1993; 87: 500-11.
43. Anderson RD, Ohman EM, Holmes DR Jr, et al. Use of intra-aortic balloon counterpulsation in patients presenting with cardiogenic shock: observations from the GUSTO-I Study. Global utilization of streptokinase and tpa for occluded coronary arteries. J Am Coll Cardiol 1997; 30: 708-15.
44. Sanborn TA, Sleeper LA, Bates ER, et al. Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK trial registry. J Am Coll Cardiol 2000; 36: 1123-1129.
45. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: a report of the ACC/AHA Task Force on practice guidelines (writing committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). Circulation 2004; 110: e82-292.
46. Wilcox RG, von der Lippe G, Olsson CG, et al. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian study of early thrombolysis (AS-SET). Lancet 1988; 2: 525-30.
47. Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study. AIMS trial study group. Lancet 1990; 335: 427-31.
48. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. ISIS-2 (Second International Study of Infarct Survival) Collaborative group. Lancet 1988; 2: 349-60.
49. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993; 329: 673-82.
50. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO angiographic investigators. N Engl J Med 1993; 329: 1615-22.
51. Kennedy JW, Gensini GG, Timmis GC, Maynard C. Acute myocardial infarction treated with intracoronary streptokinase: a report of the society for cardiac angiography. Am J Cardiol 1985; 55: 871-7.
52. Berger PB, Holmes DR Jr, Stebbins AL, Bates ER, Califf RM, Topol EJ. Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-I) trial. An observational study. Circulation 1997; 96: 122-7.
53. Urban P, Stauffer JC, Bleed D, et al. A randomized evaluation of early revascularization to treat shock complicating acute myocardial infarction. The (Swiss) multicenter trial of angioplasty for Shock-(S)MASH. Eur Heart J 1999; 20: 1030-8.
54. Stauffer JC, Urban P, Bleed D, et al. Result of the "Swiss" multi-center evaluation of early angioplasty for shock following myocardial infarction. Circulation 1997; 96(Suppl 1): I-209.
55. Schindler DM, Palmeri ST, Antonelli TA, et al. Diabetes mellitus in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK trial registry. J Am Coll Cardiol 2000; 36: 1097-103.
56. Hochman JS, Sleeper LA, White HD, et al. SHOCK investigators. Should We emergently revascularise occluded coronaries for cardiogenic shock. One-year survival following early revascularization for cardiogcnic shock. JAMA 2001; 285: 190-2.
57. Barbash IM, Behar S, Battler A, et al. Management and outcome of cardiogenic shock complicating acute myocardial infaretion in hospitals with and without on-site catheterization facilities. Heart 2001; 86; 145-9.
58. Hochman JS, Gersh BJ. Acute myocardial infarction: complications. In: Topol EJ, ed. Textbook of cardiovascular medicine. Philadelphia: Lippincott-Raven. 1998; 437-80.
59. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The primary angioplasty in myocardial infarction study group. N Engl J Med 1993; 328: 673-9.
60. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. The global use of strategies to open occluded coronary arteries in acute coronary syndromes (GUSTO IIb) Angioplasty substudy investigators. N Engl J Med 1997; 336: 1621-8.
61. O'Neill W, Erbel R, Laufer N, Walton J, Bates E, Topol E. Coronary angioplasty therapy of cardiogenic shock complicating acute myocardial infarction. Circulation 1985; 72: 309.
62. Lee L, Bates ER, Pitt B, Walton JA, Laufer N, O'Neill WW. Percutaneous transluminal coronary angioplasty improves survival in acute myocardial infarction complicated by cardiogenic shock. Circulation 1988; 78: 1345-51.
63. Landin RJ, Rothbaum DA, Linnemeier TJ, Ball MW. Hospital mortality of patients undergoing emergency angioplasty for acute myocardial infarction: relationship of mortality to cardiogenic shock and successful angioplasty. Circulation 1988; 78: 119.
64. Verna E, Repetto S, Boscarini M, Ghezzi I, Binaghi G. Emergency coronary angioplasty in patients with severe left ventricular dysfunction or cardiogenic shock after acute myocardial infarction. Eur Heart J 1989; 10: 958-66.
65. Kaplan AJ, Bengtson JR, Aronson LG, et al. Reperfusion improves survival in patients with cardiogenic shock after myocardial infarction. J Am Coll Cardiol 1990; 15: 155A.
66. Lee L, Erbel R, Brown TM, Laufer N, Meyer J, O'Neill WW. Multicenter registry of angioplasty therapy of cardiogenic shock: initial and long-term survival. J Am Coll Cardiol 1991; 17: 599-603.
67. Gacioch GM, Ellis SG, Lee L, et al. Cardiogenic shock complicating acute myocardial infarction: the use of coronary angioplasty and the integration of the new support devices into patient management. J Am Coll Cardiol 1992; 19: 647-53.
68. Moosvi AR, Khaja F, Villanueva L, Gheorghiade M, Douthat L, Goldstein S. Early revascularization improves survival in cardiogenic shock complicating acute myocardial infarction. J Am Coll Cardiol 1992; 19: 907-14.
69. Laney PL, Dell'Italia LJ, Brooks SR, et al. Follow-up exercise function in patients presenting with cardiogenic shock and acute transmural myocardial infarction. J Am Coll Cardiol 1993; 21: 77A.
70. Eltchainoff H, Simpfendorfer C, Franco I, Raymond RE, Casale PN, Whitlow PL. Early and 1-year survival rates in acute myocardial infarction complicated by cardiogenic shock: a retrospective study comparing coronary angioplasty with medical treatment. Am Heart J 1995; 130: 459-64.
71. Antoniucci D, Valenti R, Santoro GM, et al. Systematic direct angioplasty therapy and stent-supported direct angioplasty therapy for cardiogenic shock complicating acute myocardial infarction: inhospital and long-term survival. J Am Coll Cardiol 1998; 31: 294-300.
72. Webb JG, Carere RG, Hilton JD, et al. Usefulness of coronary stenting for cardiogenic shock. Am J Cardiol 1997; 79: 81-4.
73. Hasdai D, Harrington RA, Hochman JS, et al. Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation. J Am Coll Cardiol 2000; 36: 685-92.
74. Klein LW, Shaw RE, Krone RJ, et al. American College of Cardiology National Cardiovascular Data Registry. Mortality after emergent percutaneous coronary intervention in cardiogenic shock secondary to acute myocardial infarction and usefulness of a mortality prediction model. Am J Cardiol 2005; 96: 35-41.
75. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations of the American College of Cardiology/American Heart Association Task Force on practice guidelines. (Committee on management of acute myocardial infarction). Circulation 1999; 100: 1016-30.
76. DiSesa V, Patel M, Hollenberg SM. Coronary artery bypass grafting for cardiogenic shock. In: Hollenberg SM, Bates ER, eds. Cardiogenic shock. Armonk, NY: Futura. 2002; 103-17.
77. White HD, Assmann SF, Sanborn TA, et al. Comparison of percutaneous coronary intervention and coronary artery bypass grafting after acute myocardial infarction complicated by cardiogenic shock: results from the should we emergently revascularize occluded coronaries for cardiogenic shock (SHOCK) trial. Circulation 2005; 112: 1992-2001.
78. Subramanian VA, Roberts AJ, Zema MJ, et al. Cardiogenic shock following acute myocardial infarction: late functional results after emergency cardiac surgery. NY State J Med 1980; 80: 947-52.
79. Dunkman WB, Leinbach RC, Buckley MJ, et al. Clinical and hemodynamic results of intraaortic balloon pumping and surgery for cardiogenic shock. Circulation 1972; 46: 465-77.
80. Laks H, Rosenkranz E, Buckberg GD. Surgical treatment of cardiogenic shock after myocardial infarction. Circulation 1986; 74: III11-6.
81. Bardet J, Masquet C, Kahn JC, et al. Clinical and hemodynamic results of intra-aortic balloon counterpulsation and surgery for cardiogenic shock. Am Heart J 1977; 93: 280-8.
82. Menon V, Webb 1G, Hillis LD, et al. Outcome and profile of ventricular septal rapture with cardiogenic shock after myocardial infarction: a report from the SHOCK trial registry. Should we emergently revascularize occluded coronaries in cardiogenic shock? J Am Coll Cardiol 2000; 36: 1110-6.
83. Dixon SR, Alkafri H, Chami A. Clinical predictors of in-hospital death in patients with cardiogenic shock selected to undergo early revascularization. J Am Coll Cardiol 2002; 39: 808-1.
84. Norman JC, Cooley DA, Igo SR, et al. Prognostic indices for survival during postcardiotomy intra-aortic balloon pumping. Methods of scoring and classification, with implications for left ventricular assist device utilization. J Thorac Cardiovasc Surg 1977; 74: 709-20.
85. Bartlett RH, Roloff DM, Custer JR, Younger JG, Hirschl RB. Extracorporeal life support: the University of Michigan experience. JAMA 2000; 283: 904-8.
86. Vogel RA, Shawl F, Tommaso C, et al. Initial report of the National registry of elective cardiopulmonary bypass supported coronary angioplasty. J Am Coll Cardiol 1990; 15: 23-9.
87. Magliato KE, Kleishi T, Soukiasian HJ, et al. Biventricular support in patients with profound cardiogenic shock: a single center experience. ASAIO J 2003; 49: 475-9.
88. Thiele H, Lauer B, Hambrecht R, Boudriot E, Cohen HA, Schuler G. Reversal of cardiogenic shock by percutaneous left atrial-to-femoral arterial bypass assistance. Circulation 2001; 104: 2917-22.
89. Depre C, Vanoverschelde JL, Goudemant JF, Mottel I, Hue L. Protection against ischemic injury by nonvasoactive concentrations of nitric oxide synthase inhibitors in the perfused rabbit heart. Circulation 1995; 92: 1911-8.
90. Cotter G, Kaluski E, Blatt A, et al. L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardingenic shock. Circulation 2000; 101: 1358-61.
91. Cotter G, Kaluski E, Milo O, et al. LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: a prospective randomized study. Eur Heart J 2003; 24: 1287-95.
92. Ashby DT, Stone GW, Moses JW. Cardiogenic shock in acute myocardial infarction. Catheter Cardiovasc Interv 2003; 59: 34-43.